title: The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization.
abstract: BACKGROUND
  Parental immunization has been recommended as a "cocoon" strategy to prevent serious pertussis outcomes in early infancy. We illustrate the high number needed to vaccinate (NNV) for this program based on recent epidemiologic data from the provinces of Québec and British Columbia (BC), Canada.
  
  
  METHODS
  Surveillance trends were summarized for the period 1990-2010. Hospitalization, intensive care unit (ICU) admission, and mortality data were compiled from 2000 to 2009. The proportion of infant pertussis attributed to a parent was estimated at 35%, explored up to 55%. Adult vaccine efficacy (VE) was estimated at 85%. The NNV was calculated as [2 parents/(parent-attributable infant risk × parent VE)]. To capture at least 1 recent cyclical peak, NNV was derived for the period 2005-2009 and explored for peak/trough years.
  
  
  RESULTS
  Substantial decline has occurred in pertussis incidence across all age groups including infants, reaching a 20-year nadir in 2010 in both provinces. For the period 2005-2009, the risk of infant hospitalization and ICU admission was 57 and 7, respectively, per 100 000 in Québec and 33 and 7, respectively, per 100 000 in BC. In both provinces the risk of infant pertussis-related death over that period was <0.5 per 100 000. The NNV for parental immunization was at least 1 million to prevent 1 infant death, approximately 100 000 for ICU admission, and >10 000 for hospitalization.
  
  
  CONCLUSIONS
  In the context of low pertussis incidence, the parental cocoon program is inefficient and resource intensive for the prevention of serious outcomes in early infancy. Regions contemplating the cocoon program should consider the NNV based on local epidemiology.
authors.affiliation: Communicable Disease Prevention and Control Services, British Columbia Centre for Disease Control (BCCDC), Vancouver; Canada. danuta.skowronski@bccdc.ca
authors.forename: Danuta M
authors.initials: DM
authors.lastname: Skowronski
authors.forename: Naveed Z
authors.initials: NZ
authors.lastname: Janjua
authors.forename: Elodie P Sonfack
authors.initials: EP
authors.lastname: Tsafack
authors.forename: Manale
authors.initials: M
authors.lastname: Ouakki
authors.forename: Linda
authors.initials: L
authors.lastname: Hoang
authors.forename: Gaston
authors.initials: G
authors.lastname: De Serres
mesh_terms: D001955:British Columbia / Q000453:epidemiology; D002675:Child, Preschool; D006760:Hospitalization; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D015278:Intensive Care Units, Pediatric; D010290:Parents; D010567:Pertussis Vaccine / Q000008:administration & dosage* / Q000276:immunology; D011159:Population Surveillance; D011792:Quebec / Q000453:epidemiology; D012307:Risk Factors; D014611:Vaccination / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D014917:Whooping Cough / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*
chemical_list: D010567:Pertussis Vaccine